Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives.
Following the European Hematology Association (EHA) 2025 Congress in Milan, The American Journal of Managed Care® spoke with Ibrahim Aldoss, MD, associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, about early results from the phase 1/2 SYRUS study (NCT06137118) he presented at the meeting. The study evaluated the safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
In this clip, Aldoss provides background on the treatment and outlines the objectives of the SYRUS study.
This transcript was lightly edited; captions were auto-generated.
Transcript
For context, can you describe what AZD0486 is and what was known about its activity before the SYRUS study?
AZD0486 is a novel IgG [immunoglobin G] fully human CD3/CD19 bispecific T- cell engager. It's uniquely designed, with a low-affinity CD3 binding site to reduce cytokine release and CRS [cytokine release syndrome], but [it] also has a silent IgG4 Fc tail, which leads to a kind of long half-life, in the range of 12 to 15 days.
AZD0486, was evaluated and tested in [the] first-in-human study in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, and it demonstrated activity and tolerability in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. [During] the last EHA [Congress], we presented the preliminary results from the dose escalation study of the SYRUS study, where we evaluated AZD0486 in patients with relapsed/refractory B-cell ALL.
What were the primary objectives of the phase 1/2 SYRUS study? What methods did you use to investigate these?
The primary objective for the dose escalation [study] was [the] safety and tolerability of AZD0486. The secondary [objectives were] efficacy, PK [pharmacokinetics], and immunogenicity.
The SYRUS study, it has 3 parts. Part A is the dose escalation [study], where we evaluated the increase [in] the target dose of AZD0486. There [is] part B, which [is] the dose optimization [study], where we select 2 dose levels that we evaluate and compare for efficacy and toxicity. Part C [is] a dose expansion [study] where we evaluated the recommended phase 2 dosing for efficacy.
[During] EHA, we only presented the first 3 dose levels from part A of the study. AZD0486 in the SYRUS study was implemented with triple-step-up dosing, or the dose was increased from day 1, then day 4, then day 8, and the target dose was given on day 15. After that, it's given as an IV [intravenous infusion] every 2 weeks.
We evaluated AZD0486 in 3 dose levels, where we evaluated 2 step-up dosing, the low step-up dosing in dose level 1, and the higher step-up dosing in levels 2 and 3. The target dose for dose level 1 was 2.4 mg. For dose level 2, [it] was 7.2 mg. For dose level 3, [it] was 15 mg.
The key eligibility criteria [are] patients aged 16 and above with relapsed/refractory B-cell ALL expressing CD19, with any level of [CD19] expression, [and] they have to fail at least 2 prior lines of therapy. The prior exposure to CD19-targeted therapies were allowed [in] the study.
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds
August 5th 2025Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More